LRP5 and osteosarcoma: For instance, LRP5 is overexpressed in high‐grade osteosarcoma, and inhibiting the canonical Wnt/β‐catenin pathway by using a soluble dominant‐negative LRP5 could suppress the invasive capacity and epithelial to mesenchymal transition (EMT) in osteosarcoma cells.43, 44